Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2021-06-30, Stock:ABBV, The news for the past five days is as follows:
2021-06-23: nan
2021-06-24: NEWS1: AbbVie Is One Of The Biggest Pharma Companies, But Is It A Buy Right Now?.NEWS2: AbbVie Exercises Right to Acquire TeneoOne and Lead Asset TNB-383B for the Potential Treatment of Relapsed or Refractory Multiple Myeloma.
2021-06-25: NEWS1: FDA To Miss Action Dates For AbbVie's Upadacitinib Application For Psoriatic Arthritis, Ankylosing Spondylitis.NEWS2: AbbVie Provides Update Regarding RINVOQ® (upadacitinib) in Psoriatic Arthritis and Ankylosing Spondylitis in the U.S..NEWS3: 3 High-Yield Stocks With Secure Payouts.NEWS4: AbbVie Slips on FDA Delay in Arthritis-Drug Action Dates.NEWS5: AbbVie Inc. (NYSE:ABBV) is Finding Balance between Dividends and Growth.NEWS6: CHMP Recommends Approval of RINVOQ® (upadacitinib) for the Treatment of Atopic Dermatitis.
2021-06-28: NEWS1: AbbVie (ABBV) Gains But Lags Market: What You Should Know.NEWS2: AbbVie Gastroenterology Pipeline to be Featured at the 16th Congress of European Crohn's and Colitis Organisation (ECCO).NEWS3: AbbVie's (ABBV) Rinvoq sNDA Decision Delayed by the FDA.NEWS4: These 3 High-Dividend Stocks Have Cathie Wood's Seal of Approval.
2021-06-29: NEWS1: Upadacitinib (RINVOQ®) Met the Primary and All Secondary Endpoints in the 52-Week Phase 3 Maintenance Study in Ulcerative Colitis Patients.

Answer: Rise